NFKB1 and neoplasm: Combining NF-κB inhibitors with standard cancer therapies, such as chemotherapy, endocrine therapy, and immunotherapy, including IC inhibitors, could help in sensitizing tumor cells to the cytotoxic effects of the drugs, overcoming resistance mechanisms, and potentially augmenting the anti-tumor immune response.